New medications for treatment of opioid dependence have been recently approved (LAAM) or are currently under consideration for approval (buprenorphine) by FDA. Both are long-acting; buprenorphine may be unique in having a high safety profile, and limited physical dependence. Both may be useful in detoxification treatment. However, there is currently insufficient information concerning the syndrome associated with withdrawal from LAAM and buprenorphine and no systematic, well-designed, well-controlled studies comparing LAAM, buprenorphine and methadone detoxification have been conducted. Two complementary studies are proposed: 1) a residual laboratory comparison of withdrawal syndromes following abrupt discontinuation of LAAM, buprenorphine and methadone and 2) an outpatient comparison study of LAAM, buprenorphine and methadone in detoxification treatment. The first study will utilize the controlled environment of the residual research unit to obtain a detailed assessment of time course, intensity and symptom profiles during spontaneous withdrawal from methadone, LAAM and buprenorphine. Two methadone doses (30, 100 mg/day) will be included to provide relevant benchmark comparison data. The second study will assess the comparative efficacy of the three medications in outpatient detoxifications during short (10 day) and longer-term (50 day) dose tapering schedules similar to those used in non- research treatment services. A methadone maintenance conditions will provide relevant comparison data for interpreting observed withdrawal symptomatology. Both studies will utilize rigorous and proven clinical trials methodology to obtain scientifically useful data directly comparing the characteristic opioid withdrawal syndromes associated with LAAM, buprenorphine and methadone. Further, with the approval of LAAM and buprenorphine as treatment medications for opioid dependence, these studies will provide the information needed by clinicians for medications and dose selection in detoxification treatment as well as optimal dose reduction schedules for LAAM and buprenorphine.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-15
Application #
6650594
Study Section
Project Start
2002-08-15
Project End
2003-06-30
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications